Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

So What’s Next For Hanmi?

This article was originally published in PharmAsia News

Executive Summary

Hanmi's surprising success in R&D this year has left people wondering what strategy the leading South Korean pharma firm may take next to transform into a big global player like Takeda. With an expected massive inflow of cash from a series of big licensing out deals with multinationals, it may be poised to change its R&D strategy and even engage in some M&A.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC088576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel